OR WAIT 15 SECS
MedNet Solutions, a global life sciences technology solutions company specializing in clinicalstudy management systems, is pleased to announce that Allos Therapeutics’ new international disease‐specificregistry for patients with peripheral T‐cell lymphoma (PTCL) has enrolled its first study participant. This individual wasenrolled Friday, February 5th by Dr. Haluk Tezcan at the Kootenia Cancer Center in Post Falls, ID.
The registry, named COMPLETE (Comprehensive Oncology Measures for Peripheral T‐cell Lymphoma Treatment), was built using ENLIGHTEN®, MedNet’s industry‐leading EDC/eClinical technology solution. This represents the 5th disease‐specific registry built and deployed by MedNet Solutions within the last two years.
“We saw the importance of developing a global PTCL‐specific registry that addresses the urgent need to better understand the real‐world disease management across multiple treatment regimens, such as drug therapy, stem cell transplant and radiation therapy,” stated Dvorit Samid, Ph.D., vice president, Medical Affairs at Allos Therapeutics. “MedNet has done an excellent job of initiating the registry and meeting critical timelines. They worked closely with a group of prominent international multi‐disciplinary experts, serving as a steering committee, to develop this new PTCL registry ‐ named COMPLETE ‐ to prospectively study treatment patterns and patient outcomes. We are committed to this important initiative and believe that the data obtained will eventually help practitioners optimize treatment for patients with aggressive PTCL.”
The COMPLETE registry is a global 5 year observational study that will enroll newly‐diagnosed PTCL patients and collect data on longitudinal treatment patterns and outcomes. The approximately 75 sites expected to participate will represent academic, hospital and community practices across the U.S. and Europe.
“MedNet Solutions is excited to work with Allos to build a registry that will help the healthcare community increase their understanding of this terrible disease,” commented John M. (Rob) Robertson, president and CEO of MedNet Solutions. “ENLIGHTEN will provide Allos with the proven and efficient infrastructure needed to collect and analyze treatment data and outcomes.